Figure 2.

The sensitivity of CRC xenograft tumors to FL118 treatment is not associated with the expression of the CPTs target Top1: Individual xenograft tumors were first established from the corresponding CRC cell lines (RKO, LS513, LS180, LIM2551, SUN-C1, LIM2405, SW48, NCI-H716, LOVO, T84, LS411N, Caco-2, Colo205, Colo201, NCI-H747, SW837, SW1116, SW1463) by subcutaneous injection of 2 million cells at the flank area of SCID mice, respectively. Then the established tumors were inoculated into SCID mice at the flank area for testing FL118 sensitivity. FL118 treatment was initiated at the time when the inoculated individual xenograft tumors reached 100-200 mm³ (designated day 0). FL118 was administrated with the schedule of weekly x 4 (arrowed) via p.o. (per oral) routes at a dose of 10 mg/kg (MTD: maximum tolerated dose). Individual tumor curves were derived from the mean tumor sizes 0± SD from up to five mice. The small image insert within each xenograft tumor histogram is the cut-and-past Top1 expression from Figure 1.